2022 Revenues ($USD) : $27,281,000,000.00
2022 R&D spend : $4,977,000,000.00
2022 Number of Employees : 17,000
Fiscal Year End : 12/31/22
Leader : CEO Daniel O’Day

Gilead Sciences reported strong financial results for 2022, with full-year Biktarvy sales growing 20% YoY to $10.4 billion and base business growth of 8% YoY. The company's initial 2023 guidance anticipates a 4-6% growth in its base business. The recent approval of Sunlenca for heavily treatment-experienced adults with multidrug-resistant HIV infection in the U.S. and Europe marks a significant milestone for Gilead. Additionally, the company experienced impressive sales growth in oncology with Trodelvy and in cell therapy with Yescarta and Tecartus. Gilead continues to invest in its clinical programs and aims to extend its reach to more patients and challenging diseases in the coming years. —BB